1445854-01-2

Upstream product

• 1445854-00-1 methyl (E)-3-(5-(3-(4-(2-hydroxy-3,3-dimethylbutoxy)-3-methylphenyl)pentan-3-yl)-3-methylthiophen-2-yl)acrylate 
• 1445853-99-5 methyl (E)-3-(5-(3-(4-(3,3-dimethyl-2-oxobutoxy)-3-methylphenyl)pentan-3-yl)-3-methylthiophen-2-yl)acrylate 
• 1445853-98-4 methyl (E)-3-(5-(3-(4-hydroxy-3-methylphenyl)pentan-3-yl)-3-methylthiophen-2-yl)acrylate 
• 1445853-97-3 methyl (E)-3-(5-(3-(4-methoxy-3-methylphenyl)pentan-3-yl)-3-methylthiophen-2-yl)acrylate 
• 1445853-95-1 2-(3-(4-methoxy-3-methylphenyl)pentan-3-yl)-4-methylthiophene 
• 1443355-55-2 3-(4-methoxy-3-methylphenyl)pentan-3-ol 
• 1445853-96-2 2-bromo-5-(3-(4-methoxy-3-methylphenyl)pentan-3-yl)-3-methylthiophene 
• 76805-57-7 3-methyl-4-methoxypropiophenone 

Downstream Products

• 1445853-59-7 N-hydroxy-3-(5-(3-(4-(2-hydroxy-3,3-dimethylbutoxy)-3-methylphenyl)pentan-3-yl)-3-methylthiophen-2-yl)propanamide 

Relevant academic research and scientific papers

BIS-(ARYL/HETEROARYL)-METHYLENE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND THEIR USE FOR TREATING CANCER

The present disclosure relates to novel bis-(aryl/heteroaryl)-methylene compounds of formula (I) having vitamin D receptor agonist and histone deacetylase (HDAC) inhibitory efficacy as well as to methods for reducing or inhibiting the proliferation of can